KLK3 and prostate carcinoma: Significantly, this approach has identified a novel prostate cancer immunophenotyping “fingerprint” which could potentially be used to identify the presence of prostate cancer in asymptomatic men having PSA levels <20 ng ml−1; and which outperforms the predictive value of the PSA test alone.